Objectives The COVID-19 pandemic presents an urgent need to investigate whether existing
drugs can enhance or even worsen prognosis; metformin, a known mammalian target of …

Background and aims Metformin has antiviral and anti-inflammatory effects and several
cohort studies have shown that metformin lower mortality in the COVID population in a …

Objective: We sought to identify whether metformin reduced mortality from Covid19 and if
sex specific interactions exist. Design: Retrospective review of de-identified claims from …

Observational studies suggest outpatient metformin use is associated with reduced mortality
from coronavirus disease‐2019 (COVID‐19). Metformin is known to decrease interleukin‐6 …

Background Type 2 diabetes and obesity, as states of chronic inflammation, are risk factors
for severe COVID-19. Metformin has cytokine-reducing and sex-specific immunomodulatory …

Abstract Coronavirus disease 2019 (COVID-19) is a new pandemic the entire world is facing
since December of 2019. Several risk factors are identified in developing severe disease …

Metformin was proposed to be a candidate for host-directed therapy for COVID-19. However,
its efficacy remains to be validated. In this study, we compared the outcome of metformin …

Aims Metformin exerts anti-inflammatory and immunosuppressive effects. We addressed the
impact of prior metformin use on prognosis in patients with type 2 diabetes hospitalised for …

Background and aims Diabetes is one of the most common comorbidities, and it is
associated with poorer outcomes in patients with coronavirus disease 2019 (COVID-19) …

Objective: Although type 2 diabetes mellitus (T2DM) has been reported as a risk factor for
coronavirus disease 2019 (COVID-19), the effect of pharmacologic agents used to treat …